Jeff Randall

Lorin Jeffry Randall currently works at Point 5 Technologies, Inc., as Director and YM Biosciences USA, Inc., as Chief Financial Officer.
Mr. Randall also formerly worked at Nanosphere, Inc., as Chairman from 2011 to 2016, Quad Systems Corp., as Director, Acorda Therapeutics, Inc., as Independent Director from 2009 to 2023, Tengion, Inc., as Independent Director from 2011 to 2014, Rapid Micro Biosystems, Inc., as Director, Motologic, Inc., as Director, Opexa Therapeutics, Inc., as Director from 2007 to 2009, Athersys, Inc., as Independent Director from 2007 to 2022, Aurinia Pharmaceuticals, Inc., as Lead Independent Director from 2016 to 2019, i-STAT Corp., as Chief Financial Officer & Senior Vice President from 2002 to 2004, CFM Technologies, Inc., as Chief Financial Officer & Vice President from 1995 to 2001, Eximias Pharmaceutical Corp., as Chief Financial Officer & Senior Vice President from 2004 to 2006, and Greenwich Pharmaceuticals, Inc., as Chief Financial Officer & Vice President.
Mr. Randall received his Masters Business Admin degree from Northeastern University and undergraduate degree from The Pennsylvania State University.